Background <p>Predictive biomarkers for anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) therapy are needed. Here, we validated the role of PD-1 single nucleotide polymorphisms (SNPs) in predicting the development of immune-related adverse events (irAEs) in patients with advanced cancer treated with anti-PD-1/PD-L1-based immunotherapy and defined the molecular mechanisms underlying the role of identified SNP candidate.</p> Methods…
rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy
Journal for ImmunoTherapy of Cancer | | Polcaro, G., Liguori, L., Manzo, V., De Bellis, E., Stefanelli, B., Pagliara, V., Langella, M., Caputo, A., Ottaiano, A., Martinelli, R., Cascella, M., Ferrone, C., Filippelli, A., Conti, V., Pepe, S., Sabbatino, F.
Topics: skin-cancer, immunotherapy, targeted-therapy, research
Read the full article at Journal for ImmunoTherapy of Cancer